These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 21439954)

  • 21. Herstatin, an autoinhibitor of the epidermal growth factor receptor family, blocks the intracranial growth of glioblastoma.
    Staverosky JA; Muldoon LL; Guo S; Evans AJ; Neuwelt EA; Clinton GM
    Clin Cancer Res; 2005 Jan; 11(1):335-40. PubMed ID: 15671564
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differential role of EGF and BFGF in human GBM-TIC proliferation: relationship to EGFR-tyrosine kinase inhibitor sensibility.
    Bajetto A; Porcile C; Pattarozzi A; Scotti L; Aceto A; Daga A; Barbieri F; Florio T
    J Biol Regul Homeost Agents; 2013; 27(1):143-54. PubMed ID: 23489694
    [TBL] [Abstract][Full Text] [Related]  

  • 23. ERBB receptor signaling promotes ependymoma cell proliferation and represents a potential novel therapeutic target for this disease.
    Gilbertson RJ; Bentley L; Hernan R; Junttila TT; Frank AJ; Haapasalo H; Connelly M; Wetmore C; Curran T; Elenius K; Ellison DW
    Clin Cancer Res; 2002 Oct; 8(10):3054-64. PubMed ID: 12374672
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gefitinib is effective against juvenile pilocytic astrocytoma in vitro.
    Foreman NK; Gore L; Wells D; Straessle J; Heideman R; Donson AM
    Pediatr Blood Cancer; 2006 Sep; 47(3):293-8. PubMed ID: 16206208
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Aptamer targeting EGFRvIII mutant hampers its constitutive autophosphorylation and affects migration, invasion and proliferation of glioblastoma cells.
    Camorani S; Crescenzi E; Colecchia D; Carpentieri A; Amoresano A; Fedele M; Chiariello M; Cerchia L
    Oncotarget; 2015 Nov; 6(35):37570-87. PubMed ID: 26461476
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Human glioblastoma xenografts overexpressing a tumor-specific mutant epidermal growth factor receptor sensitized to cisplatin by the AG1478 tyrosine kinase inhibitor.
    Nagane M; Narita Y; Mishima K; Levitzki A; Burgess AW; Cavenee WK; Huang HJ
    J Neurosurg; 2001 Sep; 95(3):472-9. PubMed ID: 11565870
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of epidermal growth factor receptor in chordoma pathogenesis: a potential therapeutic target.
    Shalaby A; Presneau N; Ye H; Halai D; Berisha F; Idowu B; Leithner A; Liegl B; Briggs TR; Bacsi K; Kindblom LG; Athanasou N; Amary MF; Hogendoorn PC; Tirabosco R; Flanagan AM
    J Pathol; 2011 Feb; 223(3):336-46. PubMed ID: 21171079
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effect of a dimeric Affibody molecule (ZEGFR:1907)2 targeting EGFR in combination with radiation in colon cancer cell lines.
    Häggblad Sahlberg S; Spiegelberg D; Lennartsson J; Nygren P; Glimelius B; Stenerlöw B
    Int J Oncol; 2012 Jan; 40(1):176-84. PubMed ID: 21879255
    [TBL] [Abstract][Full Text] [Related]  

  • 29. ErbBs inhibition by lapatinib blocks tumor growth in an orthotopic model of human testicular germ cell tumor.
    Juliachs M; Castillo-Ávila W; Vidal A; Piulats JM; Garcia Del Muro X; Condom E; Hernández-Losa J; Teixidó C; Pandiella A; Graupera M; Casanovas O; Germà JR; Villanueva A; Viñals F
    Int J Cancer; 2013 Jul; 133(1):235-46. PubMed ID: 23292912
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cross-talk between Notch and EGFR signaling in human breast cancer cells.
    Dai J; Ma D; Zang S; Guo D; Qu X; Ye J; Ji C
    Cancer Invest; 2009 Jun; 27(5):533-40. PubMed ID: 19219656
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Erlotinib enhances the proapoptotic activity of cytotoxic agents and synergizes with paclitaxel in poorly-differentiated thyroid carcinoma cells.
    Landriscina M; Maddalena F; Fabiano A; Piscazzi A; La Macchia O; Cignarelli M
    Anticancer Res; 2010 Feb; 30(2):473-80. PubMed ID: 20332457
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Activation of ErbB3, EGFR and Erk is essential for growth of human breast cancer cell lines with acquired resistance to fulvestrant.
    Frogne T; Benjaminsen RV; Sonne-Hansen K; Sorensen BS; Nexo E; Laenkholm AV; Rasmussen LM; Riese DJ; de Cremoux P; Stenvang J; Lykkesfeldt AE
    Breast Cancer Res Treat; 2009 Mar; 114(2):263-75. PubMed ID: 18409071
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combination of the EGFR tyrosine kinase inhibitor AG1478 and 5-FU: no synergistic effect on EGFR phosphorylation, cell proliferation and apoptosis induction.
    Yagublu V; Ahmadova Z; Hajiyeva Y; Hafner M; Keese M
    Anticancer Res; 2013 Sep; 33(9):3753-8. PubMed ID: 24023306
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tumor-targeted Nanobullets: Anti-EGFR nanobody-liposomes loaded with anti-IGF-1R kinase inhibitor for cancer treatment.
    van der Meel R; Oliveira S; Altintas I; Haselberg R; van der Veeken J; Roovers RC; van Bergen en Henegouwen PM; Storm G; Hennink WE; Schiffelers RM; Kok RJ
    J Control Release; 2012 Apr; 159(2):281-9. PubMed ID: 22227023
    [TBL] [Abstract][Full Text] [Related]  

  • 35. EGFR through STAT3 modulates ΔN63α expression to sustain tumor-initiating cell proliferation in squamous cell carcinomas.
    Ripamonti F; Albano L; Rossini A; Borrelli S; Fabris S; Mantovani R; Neri A; Balsari A; Magnifico A; Tagliabue E
    J Cell Physiol; 2013 Apr; 228(4):871-8. PubMed ID: 23018838
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of the putative cancer stem cell markers and growth factor receptor expression on the sensitivity of ovarian cancer cells to treatment with various forms of small molecule tyrosine kinase inhibitors and cytotoxic drugs.
    Puvanenthiran S; Essapen S; Seddon AM; Modjtahedi H
    Int J Oncol; 2016 Nov; 49(5):1825-1838. PubMed ID: 27599579
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Downregulation of LRIG1 expression by RNA interference promotes the aggressive properties of glioma cells via EGFR/Akt/c-Myc activation.
    Xie R; Yang H; Xiao Q; Mao F; Zhang S; Ye F; Wan F; Wang B; Lei T; Guo D
    Oncol Rep; 2013 Jan; 29(1):177-84. PubMed ID: 23124613
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gefitinib inhibits sodium phosphate co-transporter III isoform 1 in a model of human malignant glioma.
    Puech C; Prevot N; Perek N
    Anticancer Res; 2014 Nov; 34(11):6527-35. PubMed ID: 25368255
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Shikonin and its derivatives inhibit the epidermal growth factor receptor signaling and synergistically kill glioblastoma cells in combination with erlotinib.
    Zhao Q; Kretschmer N; Bauer R; Efferth T
    Int J Cancer; 2015 Sep; 137(6):1446-56. PubMed ID: 25688715
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain.
    Lee JC; Vivanco I; Beroukhim R; Huang JH; Feng WL; DeBiasi RM; Yoshimoto K; King JC; Nghiemphu P; Yuza Y; Xu Q; Greulich H; Thomas RK; Paez JG; Peck TC; Linhart DJ; Glatt KA; Getz G; Onofrio R; Ziaugra L; Levine RL; Gabriel S; Kawaguchi T; O'Neill K; Khan H; Liau LM; Nelson SF; Rao PN; Mischel P; Pieper RO; Cloughesy T; Leahy DJ; Sellers WR; Sawyers CL; Meyerson M; Mellinghoff IK
    PLoS Med; 2006 Dec; 3(12):e485. PubMed ID: 17177598
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.